ReviewElectrolyte & blood pressure : E & BP2021
Metabolic Acidosis in Chronic Kidney Disease: Pathogenesis, Clinical Consequences, and Treatment.
Review in Electrolyte & blood pressure : E & BP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Veverimer in treating metabolic acidosis in chronic kidney disease patients: a systematic review and meta-analysis of randomized clinical trials.BMC nephrology · 2026Pooled it
- Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study.Clinical and experimental nephrology · 2024Trial
- [Management of recurrent urolithiasis: indications for therapy escalation and discontinuation].Urologie (Heidelberg, Germany) · 2026Review
- Article
- Risk analysis and nomogram-based prediction for Double-J stent encrustation: accounting for chronic kidney disease.Clinical and experimental nephrology · 2026Observational
- Stable bioreactor control reveals acidic pH-driven metabolic reprogramming and mitochondrial dysfunction in human lymphoblastoid cells.Communications biology · 2026Article
- Mutations in ammonia transporter RhBG that impair NHThe Journal of physiology · 2026Article
- Chronic NHScientific reports · 2026Article
- Venous blood gas kinetics and acid-base correction during incremental intermittent hemodialysis in dogs with advanced renal failure.Veterinary world · 2026Article
- Bicarbonate level in replacement fluid during CVVH: less is more!Intensive care medicine · 2026Article
- Chronic Kidney Disease, Sarcopenia, and Hormonal-Metabolic Alterations: An Intriguing Association.Kidney & blood pressure research · 2026Review
- Beyond Thirst: Influence of Bicarbonate Mineral Water on Cardiovascular Risk Factors, Gastrointestinal Function, and Liver Health.Food science & nutrition · 2025Review
- 2,3-Diphosphoglycerate: the forgotten metabolic regulator of oxygen affinity.The British journal of nutrition · 2025Review
- Optimising acid-base balance in patients with advanced chronic kidney disease: a quality improvement initiative.BMJ open quality · 2025Article
- Review
- Chronic kidney disease in the primary care setting: A narrative review.Journal of general and family medicine · 2025Review
- Metabolic Acidosis in Patients with Chronic Kidney Disease: Diagnosis, Pathogenesis, and Treatment-A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Effects of microplastics on the bones: a comprehensive review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Review
- Veverimer, a Nonabsorbed Gastrointestinal Tract HCl Binder, Decreases Renal Ammoniagenesis and Mitigates Nephrotoxic Serum Nephritis.Kidney360 · 2025Article
- Critical Review of the Benefit from Early Pharmacological and Dietary Support for Patients with Moderate-to-Severe (Non-Terminal) Chronic Kidney Disease.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kidneys play an important role in regulating the acid-base balance. Metabolic acidosis is common in chronic kidney disease (CKD) patients and can lead to poor outcomes, such as bone demineralization, muscle mass loss, and worsening of renal function. Metabolic acidosis is usually approached with evaluating the serum bicarbonate levels but should be assessed by counting blood pH. Current guidelines recommend oral bicarbonate supplementation to maintain the serum bicarbonate levels within the normal range. However, a slow decline in the glomerular filtration rate might occur, even though the serum bicarbonate levels were in the normal range. Because the serum bicarbonate levels decrease when metabolic acidosis advances, other biomarkers are necessary to indicate acid retention for early diagnosis of metabolic acidosis. For this, urine citrate and ammonium excretion may be used to follow the course of CKD patients. Metabolic acidosis can be treated with an increased fruit and vegetable intake and oral alkali supplementation. Previous studies have suggested that administration of oral sodium bicarbonate may preserve kidney function without significant increases in blood pressure and body weight. Veverimer, a non-absorbed, counterion-free, polymeric drug, is emerging to treat metabolic acidosis, but further researches are awaited. Further studies are also needed to clarify the target therapeutic range of serum bicarbonate and the drugs used for metabolic acidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.